<table>
<thead>
<tr>
<th>From</th>
<th><a href="mailto:raw@butantan.gov.br">raw@butantan.gov.br</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>To</td>
<td><a href="mailto:ssj@vsni.com">ssj@vsni.com</a> , <a href="mailto:Sumana@redcross.or.th">Sumana@redcross.or.th</a> , <a href="mailto:varaprasad@shantabitech.com">varaprasad@shantabitech.com</a></td>
</tr>
<tr>
<td>Subject</td>
<td>meeting in geneve</td>
</tr>
<tr>
<td>Date</td>
<td>Wednesday, November 19, 2003 1:37 pm</td>
</tr>
<tr>
<td>Attachments</td>
<td>DCMVN MEETING IN GENEVA.doc(21K)</td>
</tr>
</tbody>
</table>

This mail sent through IMP: http://horde.org/imp/

---

Copyright© 2003 Videsh Sanchar Nigam Limited. All rights reserved.
Click here for the Terms of Service and Privacy Policy.

http://wm3.vsnl.net/frame.html?rttPossible=true&lang=en 11/19/03
GLOBAL FORUM FOR HEALTH RESEARCH

There will be a meeting on December 2-5 in Crown Palace in Geneve. Participation in the meeting requires a fee of US $50.00. Advance registrations could be sent through Fax 44.22.791.4394.

LIVE VACCINE VECTORS.

There will be a consultation meeting, 4-5 at WHO, that I have been invited to represent DCVMN – no payment for costs. I expect to spend part of my time at that meeting.

DCVMN MEETING

In the afternoon (2pm) of December 5, which is a Friday, we will convene at WHO headquarters. A room will be assigned to us. Inquire when you arrive.

AGENDA:

1. Although I have initially submitted a long agenda, it is clear that in 3 hours we have too little time. I propose that the members present discuss what the network should do in the next years. Attempts to obtain funds failed, mostly due to the lack of clarity of what to do collectively. Certainly no grants will be available to fund the net that is basically constituted by private companies.

2. Another fundamental point is that the board must be renovated. If we feel that we do not have enough members present, we may decide to put a ballot through email.

3. Cadila Healthcare Ltd. Ahamedabad, India may be present and is asking to be a member;
ssj@vsnl.com
Message No. 2
TO: ssj@vsnl.com, marzuki@biopharma.co.id, Akira@bio.fiocruz.br
FROM: iraw@butantan.gov.br
SUBJECT: geneve meeting
Date: Thu, 02 Oct 2003 12:42:26 -0300

This mail sent through IMP: http://horde.org/imp/

Attachment of type application/msword name Geneve_meeting.doc
please download the attachment

.../getmsg.pl?id=2&shorter=ssj&loginname=ssj&sessid=1254052&POPserver=ne10/3/03
Dear Friends

We are already in October. I have reserved a room at WHO on December 5th, in the afternoon, immediately after the Global Forum meeting. Informal discussions may occur on the 3rd and 4th. Until now I have just a few confirmations. I would like to stress that the value of DCVMN for our Laboratories is invaluable. We have a presence, a word and obtain information that is relevant for each one's plans. The hope that a group of private producers would get a grant from Gates Foundation, is at least temporarily gone.

JudHAV, Akira and myself have attended a number of meetings representing DCVMN. Many have been funded by GAVI-WHO, but others at the expense of our own Laboratories. In many cases we get an invitation to close to the meeting to circulate the information and find a volunteer to represent us. I do not see, in a short term how we can find funding for this cost of meetings and other activities.

Let me suggest an agenda (basically proposed by Akira), for our half day meeting:

1. review the general objectives of DCVMN
2. elect the new board members
3. review constituency of DCVMN
4. identify areas of cooperation among the members: training, GMP, Quality assurance, etc
5. how to overcome the problems with the preparation of Protocol/documents with subjects agree by the Laboratories
6. discuss the supply chain of the production, materials and equipment and how we can obtain cost advantages as a group
7. Interchange of vaccines components
8. Joint development programs: adjuvants, merthiolate substitution, new combination vaccines, clinical trials.

This seems to be a very long list of topics for an afternoon, and we may have to restrict ourselves in discussing the objectives and goals of the DCVMN for the next 3 years and elect a board.

If only a small number will assemble in Geneva, we can discuss the just the future goals and objectives, and propose a ballot for election by email. We can also opt to have a meeting at another time and place (Akira suggests Rio in May), or consult for names and prepare a email ballot.

Please inform me by email:
1. I will be present in Geneva?
2. I cannot come and recommend to the board to offer a document for the future goals
3. I cannot come, and I am ready to vote the renovations by email
4. In the case of a. vote by email, my suggestion for are ....